Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Condition: Metastatic HPV-16 Positive Squamous Cell Anal Cancer Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin; Drug: Pembrolizumab (KEYTRUDA(R)); Biological: Individual Patient TCR-Transduced PBL Sponsor: National Cancer Institute (NCI) Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials